Hydroxychloroquine with or without macrolide and standard of care versus standard of care alone for COVID-19 cases: a systematic review and meta-analysis

Dhan Bahadur Shrestha
Mangalbare Hospital  https://orcid.org/0000-0002-8121-083X

Pravash Budhathoki
Dr Iwamura Memorial Hospital  https://orcid.org/0000-0001-8856-5417

Sitaram Khadka ( sitaram.khadka@naihs.edu.np )
Shree Birendra Hospital  https://orcid.org/0000-0002-0251-3817

Era Rawal
Kathmandu Medical College  https://orcid.org/0000-0001-9932-1039

Systematic Review

Keywords: Adverse effects, COVID-19, Hydroxychloroquine, SARS-CoV-2

Posted Date: July 7th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-39092/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at Europasian Journal of Medical Sciences on December 28th, 2021. See the published version at https://doi.org/10.46405/ejms.v2i0.377.
Abstract

Background: Coronavirus disease (COVID-19) pandemic has been a global health threat. The specific treatment of this disease has not yet been approved. In this review, we aimed at assessing the role of hydroxychloroquine with/without macrolide in terms of efficacy and adverse effects against the standard of care.

Methods: Pubmed, Medline, Google Scholar, Cochrane Library, and Clinicaltrials.gov were searched for the quantitative and qualitative synthesis of 13 studies using PRISMA guidelines for a proper review. Assessment of heterogeneity was done using the I-squared ($I^2$) test and fixed/random effect analysis was done to determine the odds/risk ratio among the selected studies.

Results: Meta-analysis of our study demonstrated no significant differences in improvement for the virological cure (RR 0.95, 0.67-1.34), whereas a significant relationship was there in radiological progression (pneumonia resolution) (RR 1.40, 1.03-1.91) between the two arms. There are 1.52 times the odds of intubation during treatment (CI 0.61-3.77), 1.08 times the risk of mortality (CI 0.65-1.79), and about 2.21 times increased risk of development of adverse effect (OR 2.21, 0.95-5.17). Though overall it is of no statistical significance, clinical relevance to thinking while using the treatment for COVID-19 is advised. Among randomized controlled trials, the treatment group has 3.5 times (OR 3.48, 1.64-7.42) higher risk of developing adverse effects. There is 2.5 times the likelihood of severe arrhythmias and QT prolongation (OR 2.49, 1.67-3.70) on the treatment arm compared to control.

Conclusion: Hydroxychloroquine with/without macrolide has shown no beneficial effect in viral clearance, survival rates while shows significant relation with the radiological improvement compared to standard of care but may increase the risk of intubation, overall side effects, and cardiac complications like arrhythmias and QT prolongation. Thus utilizing this treatment needs to be judged in clinical relevance and proper monitoring.

Background

COVID–19 pandemic has spread to the whole world and has affected millions of people. During COVID–19 cases surging up, definitive treatment for cure or prevention is not yet confirmed with a handful of evidence [1]. Due to the inadequate and uncertainty of the available therapeutic option for the cure of COVID–19, the focus is also targeted towards preventive measures for breaking the chain of transmission and even towards vaccine development simultaneously with other drug trials [2]. For quick drug development and treatment modalities; repurposing of many prior available medications is under trial. In this regard, an anti-malarial agent like hydroxychloroquine (HCQ) is one of the proposed and most interesting treatment options for COVID–19 [1,3–6]. HCQ acts as an anti-inflammatory molecule during cytokine storm in COVID–19 [7].
Meanwhile, concern arises regarding the clinical efficacy and safety of HCQ with or without macrolide as a treatment option for COVID–19. Hydroxychloroquine use can give rise to mild non-specific adverse effects like nausea, vomiting, headache to severe arrhythmias affecting multiple systems [5,8]. QT intervals prolongation is the commonest cardiac consequence of HCQ with drug-like azithromycin (AZT), for which the patient needs to be monitored carefully before other dire consequences like ventricular arrhythmias [9–11]. Metabolic derangements like hypoglycemia may also occur as other adverse consequences [12]. The increment in the dose of HCQ as compared to its regular use, which may be needed to reach SARS-CoV–2 inhibitory concentration, predisposes more to adverse effects [13,14]. Thus, we decided to evaluate the efficacy and safety concerns of HCQ with or without macrolide in COVID–19 cases. The objective is to assess differences in virological clearance, radiological improvement, overall adverse effects, severe arrhythmias, and death rate between the treatment group (HCQ with or without macrolide and standard of care) and control group (standard of care).

Methods

We used PRISMA for the systematic review of the available literature [15].

Criteria for considering studies for this review

Types of studies

We included studies conducted to determine the safety and efficacy of HCQ with/without azithromycin in addition to standard of care (SOC) for COVID–19 diagnosed cases based on guidelines with a comparison control arm were included in the present meta-analysis.

Types of participants

COVID–19 diagnosed cases based on guidelines who were enrolled either in HCQ with/without AZT in addition to standard of care or standard of care alone.

Types of interventions

HCQ with/without AZT in addition to standard of care is taken as the treatment arm and standard of care alone as a control arm.

Types of outcome measures

Clinical improvement of HCQ with/without AZT in the treatment of COVID–19; mortality rate between treatment and control group; adverse effects occurred during treatment; intubation and mechanical
ventilation requirements were outcomes of interest.

Outcomes

Clinical improvement measured as virological cure and radiological progression (pneumonia resolution), overall death between treatment and control arm, overall adverse effects occurred during treatment, and de-novo severe ECG changes in the form of QT prolongation or ventricular arrhythmias leading to the necessity to stop treatment or requiring management of the adverse cardiac event, intubation and mechanical ventilation requirement between treatment and control arm were compared.

Search methods for identification of studies

Two reviewers (DBS and ER) have independently searched and evaluated the quality of the studies using COVIDENCE and extracted data for quantitative and qualitative synthesis, which is reviewed by another reviewer for the resolution of any possible conflict (SK). Assessment of bias and cross-checking of selected studies was done by another reviewer (PB).

Electronic searches

The electronic search strategy is provided in supplementary file 1.

Data collection and analysis

We searched electronic databases like Pubmed, Medline, Google Scholar, Cochrane Library, clinicaltrials.gov, and WHO clinical trial registry. We also checked the references section from published review articles on-screen and identify additional studies for our analysis. Extracted data for quantitative synthesis was analyzed using RevMan 5.3. Heterogeneity was assessed using the $I^2$ test, and the fixed/random-effects model was used when appropriate for the pooling of studies.

Selection of studies

Due to the inadequate number of published randomized control trials and small-sized published Randomized Clinical Trials (RCTs), we also included prospective/retrospective observational studies with a comparison between HCQ with/without AZT in addition to standard of care and standard of care alone in the present meta-analysis. We excluded 8 studies lacking a control group receiving standard of care in addition to the treatment arm. We excluded 3 studies in which the outcome was compared between HCQ with/without AZT to HCQ alone or AZT alone, as our study is focused on comparing HCQ with/without AZT against the standard of care alone. We excluded the recently retracted paper of Mehra published in Lancet due to data discrepancy [16]. We also excluded commentaries, viewpoints, reviews, in-vitro studies, editorials, letters to editors, protocols, and studies done in the pediatric population.
Data extraction and management

Selected studies were evaluated for the quality of the studies and among them having the outcome of interest were included for quantitative synthesis.

Assessment of risk of bias in included studies

The Cochrane ROB tool was used to analyze the risk of bias in our included RCTs shown in figure 1. We used the NHLBI (National Heart, Lung, and Blood Institute) quality assessment tool to assess the risk of bias in our retrospective studies and cohort studies [17]. Risk-of-bias plots have been created through the RevMan 5.3.

Assessment of heterogeneity

Heterogeneity assessment was done using the $I^2$ test. Interpretation of $I^2$ test was done based on the Cochrane Handbook for Systematic Reviews of Interventions as follows: “0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity. The importance of the observed value of $I^2$ depends on (i) the magnitude and direction of the effect and (ii) the strength of evidence for heterogeneity (e.g. P-value from the chi-squared test, or a confidence interval for $I^2$).”

Assessment of reporting biases

Predetermined outcome reporting documentation assessed to assess reporting bias.

Data synthesis

Statistical analysis was performed using RevMan 5.3 software. Risk Ratio (RR)/ Odds Ratio (OR) was used for outcome estimation whenever appropriate with 95% Confidence Interval (CI). The fixed/random-effects model was used according to heterogeneities.

Subgroup analysis and investigation of heterogeneity

In the case of heterogeneity, the inverse variance, random-effect model, and exclusion of outlier studies based on weight tried. Forest plots were presented to visualize the degree of variation between studies.

Sensitivity analysis
In our study, a sensitivity analysis was performed by examining the effect of studies on the results based on their weight when considered significant, outlier studies were excluded, and the analysis was re-run.

Results

Qualitative synthesis

A total of 1385 studies were identified after electronic database searching. After 399 duplicates were removed, we screened the title and abstracts of 986 studies. 808 studies were excluded and 178 articles were seen for full-text eligibility. A total of 164 studies were excluded with definite reasons mentioned in the PRISMA flow diagram in figure 2. We included a total of 13 studies in our study. The summary of the 13 studies is discussed in table 2.

Table 1: NHLBI quality assessment tool for observational cohort and cross-sectional studies

| Study, Year       | Bias risk (out of 14, 2 points not applicable) | Percentage |
|-------------------|-----------------------------------------------|------------|
| Rosenberg [18], 2020 | 10/12                                         | 83.3%      |
| Magagnoli [19], 2020 | 9/12                                          | 75%        |
| Geleris [20], 2020  | 9/12                                          | 75%        |
| Mahevas [21], 2020  | 9/12                                          | 75%        |
| Mallat [22], 2020   | 8/12                                          | 66.6%      |
| Membrillo [23], 2020| 8/12                                          | 66.6%      |
| Yu [24], 2020       | 8/12                                          | 66.6%      |
| Lee [25], 2020      | 7/12                                          | 58%        |

Good if they fulfilled 60-100% of the tool items, Fair if 50-59% or Poor if 0-49%.

Table 2: Summary of included studies
| Study, Year | Study Type       | Study Population | Intervention | Outcome                                                                 |
|------------|------------------|------------------|--------------|--------------------------------------------------------------------------|
| Barbosa [26], 2020, USA | Quasi-randomized trial | 63               | HCQ 400 mg BD for 1-2 days followed by 200mg OD for 4 days in the treatment group | - Mortality rate 4/32 T and 1/31 C  
- Escalation of respiratory support level compared to 5 days  
Among match cases (n=38)  
- Mortality Rate 2/17 (11.76%) T and 1/21 C  
- Rate of Intubation (MV) =7/17 (41.18%) T and 2/21 (9.52%) C |
| Chen Jun [27], 2020, China | RCT | 30               | HCQ 400 mg BD for 5 days in the treatment group | - Negative viral load in 13 T and 14 C  
- Median time for the negative viral load was 4 (1, 9) days T and 2 (1, 4) days in C  
- Median time for body temperature normalization in HCQ group was 1 (0, 2) T and 1 (0, 3) day] in C  
- Radiological progression in 5 cases (33.3%) of the HCQ group and 7 cases (46.7%) of the control group  
- All patients showed improvement in follow-up examinations.  
- 4 cases in T and 3 in C had transient diarrhea and liver abnormalities |
| Chen [28], 2020, China | RCT | 62               | HCQ 400 mg BD for 5 days in treatment group | - Improvement of fever in treatment group [2.2 (0.4) days].  
- Improvement of cough in the treatment group.  
- Rash in one and headache in one patient  
- Improvement of pneumonia in 67.7% (42/62) |
| Study                  | Design                  | Participants | Intervention Details | Outcomes                          |
|-----------------------|-------------------------|--------------|----------------------|-----------------------------------|
| Gautret [29], 2020, France | RCT                     | 36 (enrolled 42) | HCQ 200 mg, TID for 10 days | Viral clearance at day-6 post-inclusion |
|                       |                         | T:20 C:16    |                      | T :- 70%(14/20) C :-12.5%(2/16) |
|                       |                         | Six HCQ treated patients were lost in follow-up during the survey (1 cured, 1 death, 1 AE) | Number of patients attaining viral clearance | HCQ + AZT : 100% (6/6) |
|                       |                         |              |                      | HCQ: 57.1% (8/14) CG: 12.5% (2/16) |
| Geleris [20], 2020, USA | Observational study     | 1376         | HCQ 600 mg BD on day 1, then 400 mg daily for a median of 5 days And AZT 500 mg on day 1 and then 250 mg daily for 4 | Mortality Rate |
|                       |                         | T: 811 C: 565 |                      | T 157/811 C 75/565 |
|                       |                         |              |                      | Rate of Intubation (MV) |
|                       |                         |              |                      | T 154/811 C 26/565 |
| Lee [25], 2020, South Korea | Retrospective study   | 72           | C=LPV/r (400/100 mg orally every 6-12 hours) T=HCQ (400 mg orally every 24 hours) | Progression of clinical disease: |
|                       |                         | T: 27 C: 45  |                      | (T 12/27; C 8/45) |
|                       |                         |              |                      | Adverse effects: |
|                       |                         |              |                      | (T 7/27; C22/45) |
|                       |                         |              |                      | Severe Effect: |
|                       |                         |              |                      | (T 1/27; C 2/45) |
|                       |                         |              |                      | Ventilation: |
|                       |                         |              |                      | (T 0/27: C 3/45) |
|                       |                         |              |                      | Death |
|                       |                         |              |                      | (T 0/27; C 2/45) |
| Magagnoli [19], 2020, USA | Retrospective Analysis | 368          | HCQ or HCQ + AZT in combination | Mortality |
|                       |                         | HCQ :- 97    |                      | (C:- 18; HCQ : - 27; HCQ + AZT :- 25) |
| Study                                      | Design Type                  | Patients | Comparator 1 (HCQ + AZT) | Comparator 2 (HCQ) | Outcomes                                                                 |
|-------------------------------------------|------------------------------|----------|--------------------------|-------------------|--------------------------------------------------------------------------|
| Mahevas [21], 2020, France                | Comparative observational    | 173      | T: 84                    | C: 89             | - Risk of ventilation (CG: 25; HCQ: 12; HCQ + AZT: 7)                    |
| Mallat [22], 2020, UAE                   | Retrospective observational  | 34       | T: 21                    | C: 13             | - Time for negative viral load (T: 17 [13-21] days; C: 10 [4-13] days)  |
| Membrillo [23], 2020, Spain              | Observational cohort study   | 166      | T: 123                   | C: 43             | - Mean hospital stay 6 (5) days in T; 5(7) days in the C                 |
| Rosenberg [18], 2020, USA                | Retrospective cohort study   | 1438     | HCQ + AZT: 735           | HCQ: 271          | - Death probability HCQ+ AZT 189/735 (25.7%); HCQ Alone 54/271 (19.9%); AZT alone 21/211 (10.0%); No drug 28/221 (12.7%) |
| Study | Design | Total | Treatment Group | Control Group | Outcome |
|-------|--------|-------|-----------------|---------------|---------|
| Tang [30], 2020, China | RCT | 150 | 75 | 75 | 6 patients in T group refused HCQ and one control patient took HCQ |
| | | | | | - Abnormal ECG |
| | | | | | - Cardiac arrest |
| | | | | | - QT prolongation |
| | | | | | - Viral clearance in 56 in C and 53 in T before 28 days |
| | | | | | - Median time for viral clearance 8d (95% CI: 5 – 10 days) in T vs 7 (95% CI: 5 – 8 days) in C |
| | | | | | - Adverse effects in 21/70 (30%) in T and 7/80 (8.8%) in C. Serious adverse event in 2 patients. Non-serious in 19/70 in T and 7/80 in C |
| | | | | | - Median time to clinical improvement was 19 in T vs 21 in C |
| Yu [24], 2020, China | Retrospective study | 550 | 48 | 502 | HCQ 200 mg BD for 7-10 days in the treatment group |
| | | | | | - Ventilator no. = 28/48 in T and 321/502 in C |
| | | | | | - Death: 8.8% (9/48) in T and 47.4% (238/502) in C |

**Quantitative synthesis of treatment outcome**

In the present meta-analysis, we have compared randomized and non-randomized studies to extract outcome on virological clearance, radiological progression, overall death, development of adverse effects (severe, minor), cardiac complications (QT-prolongation, de-novo arrhythmias), the requirement of intubation, and mechanical ventilation. Among the included studies in the meta-analysis, we found there is mild-substantial heterogeneity; which may be due to clinical and variability in study design and the risk
of bias among studies which could not be omitted fully may be due to acute surge to COVID–19 cases having diversity in presenting and getting treatment due to pandemic.

HCQ with or without AZT regimen and SOC versus SOC only; effectiveness

Among the treatment group HCQ with or without AZT in addition to SOC versus SOC, we have compared the duration of virological clearance (negative RT-PCR) and radiological progression.

**Virological clearance**

The meta-analysis of RR for HCQ with or without AZT in addition to SOC effectiveness compared with SOC alone using a random effect model among randomized and non-randomized studies showed that there were no significant differences between the two arms (RR 0.95, 95% CI 0.67 to 1.34; participants = 250; studies = 4; \(I^2 = 76\%\)). Moreover, there is no significant risk difference (RD) between the two groups for the virological cure of HCQ with or without AZT in COVID–19 patients (RD 0.04, 95% CI –0.27 to 0.34) (Figure 3a).

Sensitivity analysis for HCQ with or without AZT in addition to SOC effectiveness compared with SOC alone

To evaluate the impact of inverse RRs as well as studies’ weight on the meta-analysis results, we conducted sensitivity analyses as according to the substantial relative weight of Tang et al. on the meta-analysis, by excluding that studies, as follows no significant change, was observed (RR 1.15, 95% CI 0.53 to 2.48). (Supplementary file 2/ figures 1, 2).

**Radiological progression (pneumonia resolution)**

Among the two studies reported radiological improvement, overall RR for HCQ with or without AZT in addition to SOC compared with SOC alone using a fixed-effect model showed that there was significant improvements among treatment arm (RR 1.40, 95% CI 1.03 to 1.91; participants = 92; studies = 2; \(I^2 = 0\%\)). Additionally, there is significant RD between the two groups for radiological progression for pneumonia resolution among HCQ with or without AZT in COVID–19 patients (RD 0.22, 95% CI 0.03 to 0.41) (Figure 3b).

HCQ with or without AZT regimen and SOC versus SOC only; mortality

The meta-analysis of death outcome in comparative randomized and non-randomized studies showed no significant differences for mortality rate between HCQ with or without AZT regimen and standard treatment group compared with SOC alone (RR 1.08, 95% CI 0.65 to 1.79; participants = 4012; studies = 9; \(I^2 = 83\%\); RD –0.01, 95% CI –0.08 to 0.07) (Figure 3c).
Sensitivity analysis for HCQ with or without AZT in addition to SOC on mortality compared with SOC alone

To evaluate the impact of inverse RRAs as well as studies’ weight on the meta-analysis results, we conducted sensitivity analyses as according to the substantial low relative weight excluding four studies <50 participants in treatment groups; Barbosa 2020 [26], Gautret 2020 [29], Lee 2020 [25], and Yu 2020 [24]; with total 702 participants from all 4 studies on the meta-analysis. By excluding those studies, no significant changes were observed(RR 1.28, 95% CI 0.75 to 2.17) (Supplementary file 2/ figures 3, 4).

While swapping events between the treatment group with the control group also did not show significance in preventing from dying [(RR) (Non-event) 0.93, 95% CI 0.86 to 1.01] (Supplementary file 2/ figure 5).

HCQ with or without AZT regimen and SOC versus SOC only; mortality among RCTs

The meta-analysis of death outcome in randomized studies using fixed effect showed no significant differences for mortality rate between HCQ with or without AZT regimen and standard treatment group compared with SOC alone (RR 2.23, 95% CI 0.35 to 14.37; participants = 80; studies = 2; I² = 0%; RD 0.05, 95% CI –0.05 to 0.16) (Figure 3d).

HCQ with or without AZT regimen and SOC versus SOC only; intubation and mechanical ventilation

The meta-analysis on intubation rate and mechanical ventilation among randomized and non-randomized studies showed no significant differences between HCQ with or without AZT regimen and SOC versus SOC only about the odds of intubation during treatment (OR 1.52, 95% CI 0.61 to 3.77; participants = 3506; studies = 6; I² = 89%) (Figure 3e).

Excluding the three studies, Barbosa 2020 [26], Lee 2020 [25], and Yu 2020 [24] with substantial low relative weight (<50 participants in the treatment group) showed no significant odds of intubation during/after the beginning of treatment among HCQ with or without AZT regimen and SOC on the meta-analysis sensitivity (OR 1.72, 95% CI 0.51 to 5.83) (Supplementary file 2/ figure 7).

HCQ with or without AZT regimen and SOC versus SOC only: overall adverse effects

The meta-analysis of among randomized and non-randomized studies showed that the odds of having overall adverse effects among those under HCQ with or without AZT regimen addition to SOC regimen was approximately 2.2 times higher than SOC only taking individuals without HCQ regimen though it was not statistically significant (OR 2.21, 95% CI 0.95 to 5.17) (Figure 3f). Patients under HCQ with or without AZT regimen and SOC regimen were having 2 times higher odds of having severe adverse effects, though it is also not statistically significant (OR 2.08, 95% CI 0.40 to 10.74) (Figure 3f).
We conducted sensitivity analyses as according to the substantial relative weight of Rosenberg 2020 [18] (>500 participants in events) on the meta-analysis, by excluding that study also no statistically significant findings observed on odds of having Overall adverse effects among HCQ with or without AZT regimen and SOC on the meta-analysis (Overall: OR 2.22, 95% CI 0.61 to 8.04) (Supplementary file 2/ figure 8).

HCQ with or without AZT regimen and SOC versus SOC only: overall adverse effects among RCTs

The meta-analysis of among randomized controlled trials showed that the odds of having overall adverse effects among those under HCQ with or without AZT regimen addition to SOC regimen was approximately 3.5 times higher than SOC only taking individuals without HCQ regimen (OR 3.48, 95% CI 1.64 to 7.42; participants = 284; studies = 4; \( I^2 = 0\); RD 0.14, 95% CI 0.06 to 0.22) (Figure 3g).

**Arrhythmias and significant QT-prolongation**

The meta-analysis of non-randomized studies showed that the odds of having Arrhythmias and significant QT-prolongation among those under HCQ with or without AZT addition to SOC regimen were approximately 2.5 times higher than SOC only taking individuals without HCQ regimen (OR 2.49, 95% CI 1.67 to 3.70; participants = 1400) (Figure 3h). While for sensitivity analysis done using random effect and inverse variance, it showed no significant odds of developing arrhythmias and QT prolongation (Supplementary file 2/ figure 9).

**Clinical trials**

There are 207 trials registered focusing on the safety and efficacy of hydroxychloroquine for COVID–19 treatment along with different parameters around the globe as of 30 May 2020 [31] (Supplementary table 2). Among these, 5 trials have recently been completed. A total of 103 trials are recruiting participants, 74 trials have not yet started recruiting, 9 trials are active but not recruiting participants, and 10 trials are enrolling by invitation. Out of these, 16 trials are observational and the rest are RCTs. Altogether, 6 trials are either suspended or terminated or withdrawn due to different reasons. According to the location provided, around 42 countries are regulating trials on such subjects, where the USA is at the highest position conducting most of the 52 trials followed by France which is managing 24 trials. The largest trial is RCT conducted in Thailand with 40,000 cases, while the smallest trial is an observational type conducted in Belgium with 12 participants [31].

**Discussion**

COVID–19 pandemic has become an alarming issue as it continues to spread all over the world and affect people globally. About the impact this has made over global health, studies dedicated to finding out an effective treatment for this issue remain inadequate. Therefore, to contribute to establishing an evidence-based treatment for such an issue, this meta-analysis was done including 13 studies from all
over the globe. The drug hydroxychloroquine (HCQ) has been used as an antimalarial and anti-rheumatic
drug for a long time and its side effects have been studied well over time. Although its repurposed use in
the treatment of the newly discovered viral pandemic, COVID–19 necessitates us to look further into the
clinical efficacy of this drug in curing patients. Although few meta-analyses have been done, we found
that they were limited to small sample sizes and had some errors in data entry as well. These factors
aided in the rationale for conducting this study.

The primary outcome for the meta-analysis was the mortality rate between the treatment and control
group, 9 studies were included which showed no statistically significant difference between the two
groups (RR 1.08, 95% CI 0.65 to 1.79). This contrasts with Singh's meta-analysis which showed an
increased risk of death (RR, 2.17; 95% 1.32 to 3.57) in patients taking HCQ [32]. Our analysis contained 9
studies compared to Singh's study and a larger sample size may have led to differences in results. Our
study, however, was similar to Chacko's meta-analysis where no difference in mortality was seen (OR:
1.41, 95% CI: 0.76–2.62; p = 0.28) [33].

Evidence of adverse effects was seen in the treatment group compared to the control group with 7
studies (1756 cases) included. Overall adverse effects were present 2.2 times more in the treatment
group, although statistical significance was not established (OR 2.21, 95% CI 0.95 to 5.17), though
clinical relevance needs to be judged while using HCQ with or without AZT in treatment. However, the
overall adverse effect among the treatment arm is approximately 3.5 times (OR 3.48, CI 1.64–7.42) higher
than the control arm while taking 4 RCTs only, but the power is low because of small-sized studies. The
risk of severe side effects was 2.08 times more in the treatment group without statistical significance (OR
2.08, 95% CI 0.4 to 10.74). Chacko and Ren both found a statistically significant increased side effect risk
with the use of hydroxychloroquine [33,34]. Even though the results were not proven statistically, the
presence of side effects must be kept in mind while the use of HCQ is considered. Cardiac adverse effects
have been an important concern with the use of HCQ and a significant result establishes the need for
cautions while using the drug. The statistically significant result showing 2.49 times higher odds of having
arrhythmias and significant QT prolongation in cases treated with HCQ with/without AZT with SOC (OR
2.49, 95% CI 1.67–3.70). It is in concordance with multiple studies that have shown an increased risk of
QT among patients taking hydroxychloroquine [9,10]. Before Mehra et al's paper retraction, when we
analysed data including from that paper showed 10 times higher odds of having arrhythmias and
significant QT prolongation which has also been attached with the other portions of the analysis in the
supplementary file [Supplementary file 3][16].

The secondary outcomes for the meta-analysis were clinical improvement where no significant difference
(RR or RD) was observed based on the virological cure (negative RT-PCRs), while it showed improvement
in radiological progression where 4 studies (250 cases) and 2 studies (92 cases) were included
respectively. No improvement in virological clearance was similarly seen in Sarma, Singh, and Chacko's
meta-analysis [32,33,35]. Our finding of radiological improvement among patients taking HCQ
with/without AZT is similar to Chacko and Sarma's analysis of improvement in CT findings following
intake of HCQ [33,35].
Strength and limitations

Other meta-analyses have been performed to assess the efficacy of HCQ in COVID–19 patients, however, this meta-analysis included 13 studies that fairly increased the sample size and provides updated studies along with the sensitivity analysis that helped refine the results as most of the outcomes were in a similar direction even when the study with the most weight was excluded. Meanwhile, we do need to acknowledge the fact there have been multiple limitations to the study with mild to substantial heterogeneity, which might be due to the methodological or clinical diversity of studies as some studies had patients with severe disease while other had patients with mild disease. We included both randomized controlled trials and retrospective studies as only small size underpowered RCTs have been completed at the moment. This might have impacted the robustness of the outcome. There are evident biases in the form of selection, performance, attrition, reporting along with multiple studies. Despite the shortcomings, the meta-analysis worked on cumulating data and providing evidence for the effects of treatment modalities being used and points towards why the use of treatment must be kept under check.

Conclusion

The final synthesized evidence of the study shows no improvement in survival, need for intubation following treatment, whereas improvement in radiological progression compared to the standard of care is demonstrated. There were increased overall and severe adverse effects among all studies, although not statistically significant. While analyzing taking only RCTs, there is an increased risk of adverse effects on the treatment arm. There was statistical evidence of de-novo ECG changes like arrhythmia and QT prolongation in patients taking hydroxychloroquine with/without macrolide compared to standard of care alone. Only when large ongoing RCTs are completed, we will have less heterogeneity and biases and a further accurate assessment can be made regarding the role of hydroxychloroquine with/without macrolide in terms of efficacy and adverse effects.

Declarations

Ethics approval and consent to participate: Not applicable

Consent for publication: Not applicable

Availability of data and materials: The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests: Not applicable

Funding: Not applicable

Authors’ contributions: DBS and PB: Contributed to the concept, analysis, and interpretation of data, and conducted the meta-analysis. SRK and ER: Contributed to the literature search and analysis of data,
revised and drafted the manuscript

The author read and approved the final manuscript.

**Acknowledgements**: Not applicable

**Competing interests**: The authors declare no competing interests.

**Authors' information**:

**Affiliations**

Medical officer, Department of Emergency Medicine, Mangalbare Hospital, Morang-56600, Nepal

ORCID iD: [0000-0002-8121-083X](https://orcid.org/0000-0002-8121-083X)

Dhan Bahadur Shrestha

Medical officer, Dr Iwamura Memorial Hospital, Bhaktapur-44800, Nepal

ORCID iD: [0000-0001-8856-5417](https://orcid.org/0000-0001-8856-5417)

Pravash Budhathoki

Clinical pharmacist, Shree Birendra Hospital; Nepalese Army Institute of Health Sciences, Kathmandu-44600, Nepal

ORCID iD: [0000-0002-0251-3817](https://orcid.org/0000-0002-0251-3817)

Sitaram Khadka

Medical officer, Kathmandu Medical College, Kathmandu-44600, Nepal

ORCID iD: [0000-0001-9932-1039](https://orcid.org/0000-0001-9932-1039)

Era Rawal

**Corresponding author**

Correspondance to Sitaram Khadka
References

1. Ahmad A, Rehman MU, Alkharfy KM. An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections. Eur Rev Med Pharmacol Sci. 2020;24(7):4030–4.

2. Amawi H, Abu Deiab GI, A Aljabali AA, Dua K, Tambuwala MM. COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics. Ther Deliv. 2020;(0).

3. Dong, L., Hu, S., & Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60.

4. Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, et al. Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing. Clin Pharmacol Ther. 2020;

5. Abena PM, Decloedt EH, Bottleau E, Suleman F, Adejumo P, Sam-Agudu NA, et al. Chloroquine and hydroxychloroquine for the prevention or treatment of novel coronavirus disease (COVID-19) in africa: caution for inappropriate off-label use in healthcare settings. Am J Trop Med Hyg. 2020;tpmd200290.

6. Catalano R, Rocca R, Juli G, Costa G, Maruca A, Artese A, et al. A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. Eur J Med Chem. 2019;183:111715.

7. Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O’Callaghan A, Pardos-Gea J, Quintana A, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 2020;102569.

8. Aggarwal G, Henry BM, Aggarwal S, Bangalore S. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019. Am J Cardiol. 2020;

9. Bessière F, Roccia H, Delinière A, Charrière R, Chevalier P, Argaud L, et al. Assessment of QT Intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. 2020;

10. Bonow RO, Hernandez AF, Turakhia M. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation. JAMA Cardiol. 2020;

11. Gérard A, Romani S, Fresse A, Viard D, Parassol N, Granvuillemin A, et al. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapies. 2020;

12. Dai Y, Lin G, Shi D. Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus. Clin Ther. 2020;

13. Balevic SJ, Hornik CP, Green TP, Clowse MEB, Gonzalez D, Maharaj AR, et al. Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials. J Rheumatol. 2020;
14. Al-Kofahi M, Jacobson P, Boulware DR, Matas A, Kandaswamy R, Jaber MM, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness. Clin Pharmacol Ther. 2020;

15. Liberati A, Altman DG, Tetzlaff J, Mulrow C. G?? tzsche, PC, Ioannidis, JPA,… Moher, D.(2009). The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 62(10):e1-34.

16. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;

17. Study Quality Assessment Tools [Internet]. National Heart, Lung, and Blood Institute (NHLBI). 2020 [cited 2020 Jun 1]. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools

18. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. Jama. 2020;

19. Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. Prepr posted April. 2020;23.

20. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;

21. Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. bmj. 2020;369.

22. Mallat J, Hamed F, Balkis M, Mohamed MA, Mooty M, Malik A, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. medRxiv. 2020;

23. de Novales FJM, Ramírez-Olivencia G, Estébanez M, de Dios B, Herrero MD, Mata T, et al. Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study. 2020;

24. Yu B, Li C, Chen P, Zhou N, Wang L, Li J, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020;1.

25. Lee JE, Lee SO, Heo J, Kim DW, Park MR, Son H, et al. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of coronavirus disease 2019 with mild to moderate severity. Preprint.

26. Barbosa J, Kaitis D, Freedman R, Le K, Lin X. Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19-a quasi-randomized comparative study. Bibliovid.[cited 2020 Apr 15]. 2020.

27. Chen J, LIU D, LIU L, LIU P, XU Q, XIA L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Medical Sci. 2020;49(1):0.
28. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020;

29. Gautret P, Lagier J-C, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949.

30. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. bmj. 2020;369.

31. ClinicalTrials.gov [Internet]. NIH U.S. National Library of Medicine. 2020 [cited 2020 May 30]. Available from: https://clinicaltrials.gov/ct2/results?cond=COVID+19&term=Hydroxychloroquine&cntry=&state=&city=&dist=&Search=Search

32. Singh AK, Singh A, Singh R, Misra A. Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis. Diabetes Metab Syndr Clin Res Rev. 2020;

33. Chacko J, Brar G, Premkumar R. Hydroxychloroquine in COVID-19: A systematic review and meta-analysis. medRxiv. 2020;

34. Ren L, Xu W, Overton JL, Yu S, Chiamvimonvat N, Thai PN. Assessment of Hydroxychloroquine and Chloroquine Safety Profiles: A Systematic Review and Meta-Analysis. medRxiv. 2020;

35. Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis. J Med Virol. 2020;

**Figures**
Figure 1

Risk of bias plot
Figure 2: Flow chart for study design

Flow chart for study design
Figure 3

Forest plot a

| Study or Subgroup | HCQ+/AZT and SOC | SOC | Risk Ratio | M-H, Random, 95% CI |
|-------------------|------------------|-----|------------|---------------------|
| CHEN Jun 2020     | 13 Events 15 Total | 14 Events 15 Total | 0.93 [0.73, 1.18] |
| Gautret 2020      | 14 Events 20 Total | 2 Events 16 Total | 5.60 [1.48, 21.13] |
| Mallat 2020       | 14 Events 23 Total | 10 Events 11 Total | 0.67 [0.46, 0.98] |
| Tang 2020         | 53 Events 75 Total | 56 Events 75 Total | 0.95 [0.78, 1.15] |

Total (95% CI) 133 Events 82 Total

Heterogeneity: Tau² = 0.08; Chi² = 12.26, df = 3 (P = 0.007); I² = 76%
Test for overall effect: Z = 0.29 (P = 0.77)

Figure 3b

| Study or Subgroup | HCQ+/AZT and SOC | SOC | Risk Difference | M-H, Random, 95% CI |
|-------------------|------------------|-----|-----------------|---------------------|
| CHEN Jun 2020     | 13 Events 15 Total | 14 Events 15 Total | -0.07 [-0.28, 0.15] |
| Gautret 2020      | 14 Events 20 Total | 2 Events 16 Total | 0.57 [0.32, 0.83] |
| Mallat 2020       | 14 Events 23 Total | 10 Events 11 Total | -0.30 [-0.56, -0.04] |
| Tang 2020         | 53 Events 75 Total | 56 Events 75 Total | -0.04 [-0.18, 0.10] |

Total (95% CI) 133 Events 82 Total

Heterogeneity: Tau² = 0.08; Chi² = 24.79, df = 3 (P < 0.0001); I² = 88%
Test for overall effect: Z = 0.25 (P = 0.81)

Figure 4

| Study or Subgroup | HCQ+/AZT and SOC | SOC | Risk Difference | M-H, Random, 95% CI |
|-------------------|------------------|-----|-----------------|---------------------|
| CHEN Jun 2020     | 5 Events 15 Total | 7 Events 15 Total | 0.71 [0.26, 1.75] |
| Chen Zhaowei 2020 | 25 Events 31 Total | 17 Events 31 Total | 1.47 [1.02, 2.11] |

Total (95% CI) 46 Events 24 Total

Heterogeneity: Tau² = 0.15; Chi² = 2.26, df = 1 (P = 0.13); I² = 56%
Test for overall effect: Z = 0.39 (P = 0.69)

| Study or Subgroup | HCQ+/AZT and SOC | SOC | Risk Difference | M-H, Random, 95% CI |
|-------------------|------------------|-----|-----------------|---------------------|
| CHEN Jun 2020     | 5 Events 15 Total | 7 Events 15 Total | -0.13 [-0.48, 0.21] |
| Chen Zhaowei 2020 | 25 Events 31 Total | 17 Events 31 Total | 0.26 [0.03, 0.48] |

Total (95% CI) 46 Events 24 Total

Heterogeneity: Tau² = 0.05; Chi² = 3.47, df = 1 (P = 0.06); I² = 71%
Test for overall effect: Z = 0.44 (P = 0.68)
Figure 5

Forest plot b
Figure 6

Forest plot d

Figure 7

Forest plot e
Figure 8

Forest plot f

Figure 9

Forest plot g
### Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementaryfile1Searchengine.docx
- Supplementaryfile2excludingMehraetal.docx
- Supplementaryfile3includingMehraetal.docx
- Supplementaryfile4Prismachecklist.docx
- Supplementarytable1NHLBIqualityassessmenttool.docx
- Supplementarytable2Clinicaltrials.docx